Rani Therapeutics News and Activities

Rani Therapeutics is a company listed under the stock ticker RANI (US).

View the org chart displaying its 23 main executives

Most searched biographies at Rani Therapeutics

• Talat Imran, Chief Executive Officer
• Abe Bassan, Director
• Mir Imran, Executive Chairman of the Board

Popular executive movements at Rani Therapeutics

• Svai Sanford, who is Chief Financial Officer will soon leave the company  (posted on May 18 2026).
• Jesper Hoiland will join the company as Head of Strategy on Apr. 26, 2026  (posted on March 26 2026).
• Bella Vazquez, who was Vice President, Human Resources, is promoted to Senior Vice President, People & Administrative Services  (posted on January 30 2026).

Click here to view some more movements at Rani Therapeutics

Create your alert
to follow the executive moves at Rani Therapeutics.

Rani Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Rani Therapeutics

• Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025 - Rani Therapeutics, LLC
• Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update - Rani Therapeutics, LLC
• Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors - Rani Therapeutics, LLC
• Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules - Rani Therapeutics, LLC
• Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules - Rani Therapeutics, LLC
• Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing - Rani Therap
• Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update - Rani Therapeutics, LLC
• Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering - Rani Therapeutics, LLC
• Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery  - Rani Therapeutics, LLC
• Rani Therapeutics Announces Research Agreement with Chugai - Rani Therapeutics, LLC
• View more press releases Close

Social media about Rani Therapeutics

• Rani Therapeutics on Wikipedia, Google News & Yahoo Finance
• Rani Therapeutics on LinkedIn, X (Twitter) & YouTube